Insiders are also snapping up a large amount of stock in Alnylam Pharmaceuticals (ALNY - Get Report), a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Insiders are buying into big time strength here since shares of Alnylam Pharmaceuticals are up over 58% so far in 2012.
Alnylam Pharmaceuticals market cap of $557 million and an enterprise value of $404 million. This stock trades at a reasonable valuation, with a price-to-sales of 6.66 and a price-to-book of 4.62. Its estimated growth rate for this year is 3.7%, and for next year it's pegged at -73.3%. This is a cash-rich company, since the total cash position on its balance sheet is $146.40 million and its total debt is zero.A director just bought 93,000 shares, or about $1 million worth of stock, at $10.75 per share. From a technical perspective, ALNY is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been in a monster uptrend for the past two months and change, with the stock rising from its November low of $6.50 to its current price of just above $13 a share. During that huge uptrend, this stock has been consistently making higher lows and higher highs, which is bullish price action. Now the stock is within range of triggering a near-term breakout trade. If you're bullish ALNY, I would look for long-biased trades once this stock breaks out above some near-term overhead resistance at $12.99 to $13.25 a share with big volume. Look for volume on that move that registers near or well above its three-month average volume of 433,223 shares. At last check, ALNY has hit a high today of $13.19 and volume is just over 200,000 shares. I also featured ALNY recently in " 8 Stocks Rising on Huge Volume." To see more stocks with notable insider buying like AutoNation (AN), Genomic Health (GHDX) and Geoeye (GEOY), check out the Stocks With Big Insider Buying portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.